Physician profile
Christopher M Kellogg
NPI 1740254457
$6,139.72
in general payments reported to CMS, 2019-2025
32 companies · $643 in 2025
The $643 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $403 · 2021: $1,210 · 2022: $1,353 · 2023: $895 · 2024: $703 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.61 |
| Education | $254.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,045.97 | 2019-2025 | Darzalex, Tecvayli |
| Pfizer INC. | $882.04 | 2019-2025 | |
| Celgene Corporation | $558.24 | 2020-2025 | Reblozyl, Opdualag |
| Genentech USA, INC. | $498.48 | 2019-2024 | Venclexta, Polivy, Columvi |
| Novartis Pharmaceuticals Corporation | $465.48 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $431.79 | 2019-2024 | Opdivo |
| Daiichi Sankyo INC. | $303.93 | 2020-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $289.59 | 2019-2024 | Enhertu |
| Array Biopharma INC | $185.53 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Mirati Therapeutics, INC. | $178.83 | 2023-2024 | Krazati |
| Astellas Pharma US INC | $168.97 | 2020-2023 | Xtandi |
| Abbvie INC. | $162.21 | 2021-2025 | |
| Kite Pharma, INC. | $132.57 | 2020-2023 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $126.99 | 2021-2023 | Imbruvica, Epkinly |
| Seagen INC. | $106.64 | 2020-2023 | Tukysa |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $103.23 | 2023-2025 | Zejula, Jemperli, Ojjaara |
| Merck Sharp & Dohme LLC | $90.95 | 2019-2024 | Keytruda |
| Amgen INC. | $57.13 | 2021-2023 | Kyprolis |
| Bayer Healthcare Pharmaceuticals INC. | $42.10 | 2020-2021 | |
| Stemline Therapeutics INC. | $41.80 | 2023 | Orserdu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.55 | 2019 | |
| Exelixis INC. | $32.37 | 2022 | |
| Sun Pharmaceutical Industries INC. | $30.28 | 2020-2022 | |
| Aveo Pharmaceuticals, INC. | $29.74 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $25.99 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $21.70 | 2020 | |
| Amneal Pharmaceuticals LLC | $19.64 | 2025 | Alymsys |
| Tesaro, INC. | $17.28 | 2019 | |
| Genzyme Corporation | $14.36 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $13.74 | 2021 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Incyte Corporation | $11.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kellogg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.